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Abstract
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. According to official reports from 121 countries
across five WHO regions, there were 213 899 newly diagnosed cases in 2014. Although leprosy affects the skin and
peripheral nerves, it can present across a spectrum of clinical and histopathological forms that are strongly influenced
by the immune response of the infected individuals. These forms comprise the extremes of tuberculoid leprosy
(TT), with a M. leprae-specific Th1, but also a Th17, response that limits M. leprae multiplication, through to lepromatous
leprosy (LL), with M. leprae-specific Th2 and T regulatory responses that do not control M. leprae replication but rather
allow bacterial dissemination. The interpolar borderline clinical forms present with similar, but less extreme, immune
biases. Acute inflammatory episodes, known as leprosy reactions, are complications that may occur before, during or
after treatment, and cause further neurological damages that can cause irreversible chronic disabilities. This
review discusses the innate and adaptive immune responses, and their interactions, that are known to affect
pathogenesis and influence the clinical outcome of leprosy.
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Introduction
Leprosy is a human chronic infectious disease caused by
the bacillus Mycobacterium leprae. It is an ancient afflic-
tion that continues to have a significant global impact
with official reports from 121 countries across five
WHO regions recording 213 899 newly diagnosed cases
in 2014 [1].
M. leprae is an alcohol acid-resistant bacilli with a
remarkedly slow replication rate that, to date, has eluded
attempts to culture it axenically in vitro [2, 3]. Although
leprosy affects the skin and peripheral nerves and can cause
irreversible impairment of nerve function and chronic
disability, it is believed that the main route of M. leprae
transmission is via the airways [4]. However, anecdotal
reports strongly suggest that trauma-related transmission is
likely, and there is also the strong suggestion of zoonotic
leprosy cases resulting from contact with armadillos and
the demonstration of environmental reservoirs such as
water sources and amoebal cysts [5, 6].
Leprosy patients can present across an extremely wide
spectrum. The Ridley and Jopling classification involves
clinical, pathological, bacilloscopic, and immunological
criteria, allowing a thorough characterization of six forms:
the polar tuberculoid (TT) and lepromatous leprosy (LL)
forms, as well the intermediate borderline tuberculoid
(BT), borderline borderline (BB), and borderline leproma-
tous (BL) forms [7–9]. A sixth classification, indeterminate
leprosy (IL), is also commonly used.
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Even after treatment, patients require regular follow-up
as they often present with tissue-damaging inflammatory
leprosy reactions or may already have permanent neuro-
logic deficit [10]. The spectral nature of the disease is
closely associated with the type of immune response in the
infected individual, making it an attractive system to inves-
tigate the immune regulation and pathogenic mechanisms,
as well as the influence of host genetics upon these [10, 11].
Indeed, studies over the past 30 years have identified
various determinants of leprosy and have illuminated the
contribution of immunopathogenesis to disease. Many gaps
remain in our knowledge and an improved understanding
would provide insight toward not only leprosy but other
infectious and immune-mediated diseases. This review
outlines the current understanding of the innate and adap-
tive immune responses against M. leprae and their role in
determining disease outcome.
Immunopathogenic mechanisms of differing
leprosy presentations
The cardinal signs of leprosy are skin lesions with
altered sensation, thickened peripheral nerves, and the
presence of alcohol acid-resistant bacilli. According to
the World Health Organization (WHO) classification,
based on smear examination or the number of lesions at
diagnosis, the patients are classified into two operational
groups that guide treatment: multibacillary (MB, more
than five skin lesions or positive smear) and paucibacillary
(PB, less than 5 lesions) [12]. Skins lesions from the
extreme PB form, TT, are hypopigmented, well-bordered
and with a low bacillary load. The extreme MB form, LL,
is characterized by poor granuloma formation, several
infiltrated skin lesions with high bacterial load. Bordeline
leprosy is characterized by multiple irregular and coales-
cent lesions, with a ‘Swiss cheese’ aspect and usually
positive baciloscopy [13]. PB leprosy patients are treated
for 6 months with a cocktail consisting of rifampicin and
dapsone. Due to their increased infection status, MB
leprosy patients are treated for 12 months with clofazi-
mine in additon to rifampicin and dapsone.
Polarization of the immune response specific toM. leprae
is an important element in the pathogenesis of leprosy and
in determining the clinical manifestation. A T helper (Th) 1
cytokine response has been documented at the lesional
levels of TT, while a Th2 cytokine response are associated
to LL forms of leprosy [14]. The immune response of TT
patients is characterized by a Th1 cytokine response (inter-
feron gamma [IFN-γ], interleukin (IL)-2, IL-15, and tumor
necrosis factor [TNF]), vigorous T-cell responses to M.
leprae antigens, and containment of the bacilli in well-
formed granulomas [2, 15]. In TT lesions, macrophages are
activated so that they resemble epithelial cells (at this point,
they are called “epithelioid cells”), and CD4+ T cells are the
predominant cell type. There is little evidence of M. leprae-
specific humoral immunity [15, 16]. In contrast, the
immune response of LL patients is characterized by a Th2
immune profile with production of IL-4 and IL-10 and acti-
vation of T regulatory cells (T reg), robust but not protect-
ive antibody production including formation of immune
complexes, and failure to restrict M. leprae growth. Com-
pared to TT, lesions from LL patients are relatively deficient
in CD4+ T cells, but rather have numerous CD8+ T cells
and macrophages heavily infected with bacilli that develop
a characteristic foamy appearance [15–19]. Palermo et al.
reported a higher number of Tregs and greater expression
of IL-10 and cytotoxic T lymphocyte antigen-4 (CTLA-4)
in LL lesions than TT lesions [20].
The balance of Th1/Th2 responses alone, however,
cannot fully explain the response in leprosy. Other T cell
subsets, such as T regulatory and Th17 cells, have been
identified as having important roles in determining host
immunity. FoxP3 positive regulatory T cells (Treg) produ-
cing TGF-β can suppress effector T cell function and were
increased in stable lepromatous patients, which may
explain the anergy associated with this leprosy clinical
form [21]. Conversely, Th17 cells produce IL-17A, IL-17F,
IL-21 and IL-22, leading to tissue inflammation and de-
struction, neutrophil recruitment, activating macrophages,
and enhancing Th1 effector cells [21–23]. Th17 cells were
first identified in experimental encephalitis and subse-
quently in rheumatoid arthritis, leishmaniasis and tubercu-
losis [21, 23]. Although several studies have demonstrated a
protective role of IL-17 against other intracellular patho-
gens and associated diseases, relatively few reports have
investigated the role of these cytokines in leprosy [21, 24].
Okada and colleagues (2015) studied families with suscepti-
bility to Candida albicans and Mycobacterium infection
and described a bi-allelic RORC mutation that resulted in
the absence of IL-17A/F–producing T cells in these individ-
uals, an impaired IFN- response to Mycobacterium [24].
Sadhu and colleagues demonstrated that Th17 cells are
more frequent in BT and TT patients, as compared to BL
and LL patients, and these cells potentiate IFN-γ produc-
tion and inhibit IL-10 production by T regulatory cells. This
suggests that Th17 cells also have a protective function
against M. leprae infection [15].
The borderline forms are immunologically dynamic.
There is a mixed histopathological aspect and a pro-
gressive reduction of the cell-mediated response from
the BT to the BB and BL forms, accompanied by more
numerous neurocutaneous lesions and increased bac-
terial load [4].
In an unusual presentation of leprosy, 5–15% of patients
can present with a pure neuritic form (PNL) characterized
by asymmetric involvement of peripheral nerves, but
absence of cutaneous manifestations. This condition may
be manifested as paresthesia or anesthesia, or a change in
muscle strength [20].
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Contribution of early events in defining clinical
outcome
The innate immune response appears critical in defining
the course of M. leprae infection and, ultimately, the
clinical outcome (Fig. 1). M. leprae bacilli are initially
recognized by several innate immune receptors, including
Toll-like receptors (TLR). M. leprae predominantly acti-
vates the TLR2/1 heterodimer expressed in macrophages
of the skin, which mediates cell activation to initiate killing
of M. leprae. TLR2 and TLR1 are more strongly expressed
in lesions of the localized TT form as compared with the
disseminated LL form of the disease [25–28]. Schwann
cells can also express TLR2 and the activation of TLR2 on
these cells contributes to nerve damage in leprosy [29].
Cytokines such as IL-15 and IL-10 are differentially pro-
duced during the innate immune response and are known
to regulate macrophage function. IL-15 is expressed in TT
lesions and induces antimicrobial activity and the vitamin
D-dependent antimicrobial program in macrophages,
resulting in phagocytosis of mycobacteria that restricts the
ability to establish infection [30]. In LL patients, IL-4 both
downregulates TLR2/1 expression and inhibits the TLR2/
1-induced cytokine response of macrophages. While IL-10
has no direct effect on TLR2/1 expression, it can strongly
inhibit TLR2/1-induced cytokine release [26].
Activation of leukocyte immunoglobulin-like receptor
subfamily A member 2 (LILRA2), expressed in several im-
mune cells including macrophages, may control the ability
Fig. 1 Immune response in the polar clinical forms of leprosy. a In tuberculoid leprosy (TT) patients, the innate immune response is activated by M.
leprae through toll-like receptors (TLR2/1). IL-15 stimulates the vitamin D-dependent antimicrobial program in macrophages and inhibits phagocytosis
of mycobacteria. These events promote a Th1 T-cell cytokine response (IFN-γ, IL-2, TNF, and IL-15) that contains the infection in well-
formed granulomas, and a Th17 response (IL-17A, IL-17F, IL-21 and IL-22) that leads to tissue inflammation and destruction, neutrophil
recruitment, macrophage activation, and enhancement of Th1 effector cells. b In lepromatous leprosy (LL) patients, IL-4, IL-10, leukocyte immunoglobulin-
like receptor subfamily A member 2 (LILRA2), and oxidized phospholipids inhibit TLR2/1-induced cytokine responses but preserve IL-10 release. In addition,
immune complexes trigger IL-10 production and increase phagocytosis of M. leprae, ApoB, haptoglobin-hemoglobin complex and oxidized phospholipids
by macrophages through the receptors CD209 and CD163, without activating the vitamin D-dependent antimicrobial pathway. The foamy appearance of
macrophages is due to the accumulation of lipid droplets (LD) inside these cells. There is an upregulation of perilipin and the adipose
differentiation-related protein in the endoplasmic reticulum–Golgi complex with the formation of vesicles containing lipids, phospholipids,
cholesterol ester, and cholesterol. Further, there is an increase in both the synthesis of LDL receptors (such as CD36, LDL-R, SBA-1, SR-B1,
and LRP-1) and uptake of endogenous cholesterol that accumulates intracellularly. This induces a Th2 and Treg immune profile, with the
production of IL-4 and IL-10, antibody production, absence of granulomas, and failure to restrict M. leprae growth [26, 31, 32, 41–46]
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of the innate immune system to activate the adaptive T
cell response. Although the ligand for LILRA2 has not
been identified, its activation inhibits TLR2/1-induced IL-
12 release but maintains IL-10 release, and while the
mechanism of LILRA2 activation during leprosy remains
uncertain, LILRA2 is notably more highly expressed in LL
than in TT lesions [31]. The LILRA2-expressing cells
identified in LL lesions belong to a monocyte/macrophage
lineage and co-express CD209, which is essential in
mediating the uptake of mycobacteria by macrophages.
Accordingly, expression of CD209 increases the uptake
of M. leprae, resulting in higher bacterial loads. Simi-
larly, oxidized phospholipids inhibit TLR2/1-induced
IL-12 release, but preserve IL-10 release [32]. Immune
complexes, which are abundant in the LL form due to
the large quantity of antibodies that are produced, can
trigger macrophages to produce IL-10 [33, 34].
The phagocytic program induced in macrophages by IL-
10 is most apparent in leprosy patients that progress to the
extreme LL clinical form [33, 34]. IL-10-stimulated macro-
phages enhance phagocytosis of both oxidized low-density
lipoprotein and mycobacteria, but without triggering the
vitamin D-dependent antimicrobial pathway. This diver-
gence between the phagocytic and antimicrobial pathways
likely promotes an intracellular environment that favors
mycobacterial survival. IL-10-programmed macrophages
are characterized by high expression of C-type lectin recep-
tors (CD209 and CD206) and scavenger receptors (CD163,
SR-A, CD36, and MARCO). CD163 mediates the uptake of
hemoglobin-haptoglobin complex, thus providing a source
of iron for mycobacterial survival [35], and triggers further
IL-10 production [36]. All of these C-type lectin and
scavenger receptors are implicated in the uptake of
apoptotic cells, apoprotein B (ApoB), lipids and lipopro-
teins, that are nutrient sources for M. leprae [37], and are
also associated with functions related to the maintenance
of tissue homeostasis by macrophages [37–40]. Lipid up-
take also inhibits the innate immune response against the
bacteria by diminishing TLR-induced antimicrobial activity
and by skewing the cytokine balance toward IL-10 secretion
whilst inhibiting IL-12 production [41]. This IL-10-derived
macrophage pathway is found in the MB forms and
enhances phagocytosis of oxidized phospholipids and add-
itional M. leprae. Studies have shown a colocalization of
the CD209 and CD163 markers, M. leprae, apoprotein B,
and host-derived oxidized phospholipids within the phago-
somes [26, 41]. Biopsies from LL patients exhibit macro-
phages that are packed with lipid droplets (LD), named
“foamy macrophages” [42, 43]. Additional mechanisms
such as enhanced cell survival through decreased apoptosis
may also contribute to the foamy macrophage characteristic
of LL lesions [44]. Schwann cells (SC) from LL patients also
have a foamy phenotype, and LD accumulation seems to be
associated with the pathophysiology of leprosy [45, 46].
As the most efficient antigen-presenting cells, dendritic
cells (DC) play an important role in connecting innate
and adaptive immunity but the actual contribution of DC
subsets to the pathogenesis of leprosy remains controver-
sial. Whereas some studies have reported a larger number
of DC in the lesions of TT patients [47, 48], others have
suggested that plasmocytoid DC are not involved in host
responses against M. leprae [49, 50].
Immunopathogenesis of leprosy reactions
In the complex evolution of leprosy, two types of spon-
taneous acute inflammatory phenomena, are known to
occur. These “leprosy reactions” occur in 30–50% of
patients at some time during the course of their disease
[51, 52]. Reactions can present with intense neural
inflammation, resulting in sudden and even permanent
loss of sensory, autonomic and motor functions. Besides
aggravating the neural lesions, reactions frequently
require prolonged treatment with toxic drugs such as
corticosteroids and/or thalidomide, which is a major
concern for the leprosy patients.
Reactions are classified into two main types: Type I re-
actions, also commonly known as reversal reaction (RR),
and Type II reaction, commonly known as erythema
nodosum leprosum (ENL) [51, 52]. The mediators of
tissue damage in these reactions are partially known,
with increased amounts of Th1 cytokines such as IFN-γ,
IL-12, and IL-2 clearly demonstrated in both RR and
ENL [51, 53] (Fig. 2). It remains unclear, however,
whether the inflammatory profile observed in the lesions
or blood during reactions is the cause or consequence of
these reactions.
Type I reactions (RR)
RR occurs in 30% of patients and involve a sudden activa-
tion of an inflammatory response to M. leprae antigens. RR
are the main cause of nerve damage in leprosy and occur
most frequently after the initiation of treatment, most often
arising in the first two months after the initiation of chemo-
therapy. This reflects a switch from a Th2-predominant
toward a Th1 response [17, 53–57]. Affected patients
present with swollen hands and feet, exacerbation of cuta-
neous lesions and neural involvement, that can result in
hospitalization [55, 58].
Both innate and adaptive immune responses participate
in the pathogenesis of RR. RR lesions are associated with a
type-IV (or delayed-type) hypersensitivity reaction and
immunophenotyping studies have indicated that the
number and percentage of CD4+ T cells are increased in
reacting skin lesions [4, 59, 60]. The vitamin D-dependent
antimicrobial pathway is activated, and IL-1, IL-2, IL-6, IL-
8, IL-12 p40, IFN-γ, TNF, IL-2 receptor [61], and CXC
chemokine-10 (CXCL10 or IP10) are detected in the circu-
lation and cutaneous lesions [60]. The tumor necrosis
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factor superfamily (TNFSF) is essential for the induction of
programmed cell death and costimulation of distinct cell
types [62, 63] and the TNFSF15 locus has been associated
with susceptibility for leprosy in Chinese individuals. A
recent study from Brazil and Vietnam reported that the
TNSF8 locus, but not the TNFSF15 locus, confers suscepti-
bility to RR [62]. Overall, the cytokine expression pattern in
the RR lesions indicates enhancement of the Th1 response
with accompanying, or related, activation of the innate
immune response and inflammatory products.
Type II reactions (ENL)
ENL affects patients with poor cellular immune responses
but who have preserved humoral responses, and thus
presents in MB patients with high levels of anti-M. leprae
immunoglobulins. ENL is characterized by an abrupt
onset of erythematous and painful nodules accompanied
by systemic symptoms such as fever, lymph node infarc-
tion, bone tenderness and hepatosplenomegaly. Neuritis
can persist for years as a chronic and recurrent symptom
in most patients [64].
ENL is usually initiated by deposition of immune com-
plexes and activation of the complement cascade, resulting
in vasculitis or a type-III hypersensitivity reaction [7]. High
immunoglobulin levels and low levels of complement
components (a sign of complement activation) can be de-
tected along with the presence of platelet-derived growth
factor BB (PDFG-BB) [60, 65]. PDFG-BB is known to pro-
mote angiogenesis and is a potential marker of ENL [65].
ENL lesions present with deposits of immunoglobulins,
complement and some mycobacterial constituents [66],
along with expression of IL-6, IL-8, and IL-10 mRNA and
sustained expression of IL-4 and IL-5 mRNA, consistent
with neutrophil chemotaxis and antibody production [67].
Tissue infiltration by CD4 cells and neutrophils occurs
[64]. The same cytokines as mentioned earlier for RR are
also found at high levels in the plasma during ENL, but in
ENL there are significantly higher levels of IL-4, IL-5, IL-
10, IL-6, IL-7 and TNF [60, 61, 68–72]. The most severe
reactions are associated with increased production of TNF
and IFN-γ and IFN-γ injections have been shown to acti-
vate ENL lesions [52, 73, 74]. While FoxP3 expressing
Treg producing TGF-β are increased in stable leproma-
tous leprosy patients, patients with reactions exhibit an
imbalance in Th17 and Treg populations [22]. These data
suggest that Treg may exert control on the inflammatory
response during leprosy reactions.
Moreover, Vieira et al. determined either the frequency
of circulating Tregs in patients with RR and ENL or the
frequency of Tregs and interleukin IL-17, IL-6, and
Fig. 2 Immunological aspects of leprosy reactions. a RR represents a type IV hypersensitivity reaction. Sudden activation of an inflammatory response
to M. leprae antigens, often after the initiation of treatment, triggers a transient conversion from a Th2 toward a Th1 response. The cytokine expression
pattern in lesions indicates enhancement of the Th1 response along with activation of the innate response and inflammatory products. b ENL involves
high levels of TNF, immune complex-associated vasculitis, and intralesional infiltration of neutrophils, eosinophils, and CD4+ T cells. ENL is initiated by
the deposition of immune complexes and activation of complement, triggering elevation of several pro-inflammatory cytokines, neutrophilic infiltrates,
and vasculitis [61–64, 82, 83]
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(TGF)-β-expressing cells not only peripheral blood but in
biopsies taken before and during the reaction episodes.
Their results suggest that in ENL, downmodulation of
Tregs may influence the development of Th-17 responses
that characterize this reaction [75].
Early diagnosis of leprosy reactions is crucial for efforts
to reduce tissue damage and prevent disabilities. Khadge
and colleagues (2015) showed that in newly diagnosed
patients from Bangladesh, Brazil, Ethiopia and Nepal the
production IFN-γ, IP-10, IL-17 and VEGF in supernatants
from M. leprae antigen-stimulated cells increased during
type 1 reaction, as compared to patients without leprosy
reactions [76]. There is, however, a lack of biomarkers that
are capable of reliably predicting reactions within endemic
populations [76].
Neuropathy
Nerve injury is the hallmark of progressive M. leprae
infection and is present in all forms of leprosy [77–79].
Physical impairment in leprosy is defined as any reduction
in sensory or motor functions. Since neurological involve-
ment is inherent to all forms of leprosy, disability is a fre-
quent complication, resulting from the natural course of
disease [58]. The major determinant of neuronal injury is
the ability of M. leprae to bind and infect SC. M. leprae
phenolic glycolipid (PGL)-I interacts with the laminin-2
receptor located on the SC membrane [53, 80–82] and
laminin-binding protein 21 (LBP21) mediates the intracel-
lular entry of M. leprae into the SC [82, 83].
In TT patients, neural damage has a direct positive
correlation with IFN-γ [67]. The activated Th1 response
and development of strong cellular immunity contribute
to the formation of tuberculoid granulomas and caseous
necrosis, and may culminate in the appearance of ab-
scesses and complete destruction of the nerves [4]. In
contrast, in LL patients exhibiting Th2 responses, the
neuropathy is directly related to the M. leprae infection
of peripheral nerves.
Conclusions
Our current knowledge postulates that the initial inter-
action between the M. leprae and the host innate immune
response impacts the initial growth and establishment of
infection, then potentially influencing the type of adaptive
immune response that is induced against the infection.
Although considerable progress has been made in under-
standing leprosy and the factors involved in its clinical out-
comes, an improved understanding of the early events of
M. leprae infection are needed. This will hopefully help us
better understand the diverse pathogenic events that can
occur later in infection, to predict clinical outcomes and
risk for complications, make improvements in drug design
and individualized therapies possible, and to reveal the
potential for novel immunotherapies. Given its spectral
presentation leprosy is an instructive human disease that
allows for direct and controlled comparison of immune
responses, in particular, CD4 T cell differentiation and dis-
coveries in leprosy can therefore provide critical insight that
can be applied to other immune- and pathogen-mediated
diseases.
Additional file
Additional file 1: Multilingual abstracts in the six official working
languages of the United Nations. (PDF 1008 kb)
Abbreviations
ApoB: Apoprotein B; BB: Borderline borderline; BL: Borderline lepromatous;
BT: Borderline tuberculoid; CTLA-4: Cytotoxic T lymphocyte antigen-4;
ENL: Erythema nodosum leprosum; IFN-γ: Interferon gamma; IL: Indeterminate
leprosy; IL: Interleukin; IL-10: Interleukin-10; LBP21: Laminin-binding protein 21;
LD: Lipid droplets; LILRA2: Leukocyte immunoglobulin-like receptor subfamily A
member 2; LL: Lepromatous leprosy; MB: Multibacillary; PB: Paucibacillary;
PGL: Phenolic glycolipid; PNL: Pure neuritic form; RR: Reversal reaction;
SC: Schawnn cell; T regs: T regulatory cells; Th1 cell: T helper 1cell; Th17: T
helper 17 cell; Th2 cell: T helper 2 cell; TLRs: Toll-like receptors; TNF: Tumor




This work was supported by the Conselho Nacional de Desenvolvimento
Científico e Tecnológico – CNPq, Edital MCT/CNPq No 14/2009 – Universal,
the Fundação de Apoio à Pesquisa e à Inovação Tecnológica do Estado de
Sergipe – FAPITEC/SE/Conselho Nacional de Desenvolvimento Científico e
Tecnológico – CNPq, EDITAL FAPITEC/SE/FUNTEC/CNPq No. 12/2009
(Programa de Núcleos de Excelência – PRONEX), Process no. 019.203.02712/
2009-8 and American Leprosy Missions. MS and RAC received a fellowship
from CAPES. ARJ is a CNPq investigator.
Availability of data and materials
For this review we used the freely available literature databases “PubMed”
and “Scopus”. The references that were not open access, were accessed by
“Portal CAPES”.
Authors’ contributions
All authors contributed equally to this work. All authors read and discussed
the issues adressed in this review. TRM and ARJ also designed the figures.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Medicine, Molecular Biology Laboratory, University Hospital,
Universidade Federal de Sergipe, São Cristóvão, Sergipe, Brazil. 2Infectious
Disease Research Institute, Seattle, USA. 3Instituto de Investigação em
Imunologia, Institutos Nacionais de Ciência e Tecnologia, CNPq, São Paulo,
SP, Brazil.
Received: 16 May 2016 Accepted: 20 December 2016
References
1. Global leprosy update, 2014: need for early case detection. Wkly Epidemiol
Rec. 2015;90:461–74.
Fonseca et al. Infectious Diseases of Poverty  (2017) 6:5 Page 6 of 8
2. Bhat RM, Prakash C. Leprosy: an overview of pathophysiology. Interdiscip
Perspect Infect Dis. 2012;2012:181089.
3. Lastoria JC, Abreu MA. Leprosy: review of the epidemiological, clinical, and
etiopathogenic aspects—part 1. An Bras Dermatol. 2014;89:205–18.
4. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL.
The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338–81.
5. Bratschi MW, Steinmann P, Wickenden A, Gillis TP. Current knowledge on
Mycobacterium leprae transmission: a systematic literature review. Lepr Rev.
2015;86:142–55.
6. Wheat WH, Casali AL, Thomas V, Spencer JS, Lahiri R, Williams DL,
McDonnell GE, Gonzalez-Juarrero M, Brennan PJ, Jackson M. Long-term
survival and virulence of Mycobacterium leprae in amoebal cysts. PLoS Negl
Trop Dis. 2014;8:e3405.
7. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A
five-group system. Int J Lepr Other Mycobact Dis. 1966;34:255–73.
8. Ridley DS. Histological classification and the immunological spectrum of
leprosy. Bull World Health Organ. 1974;51:451–65.
9. Rodrigues Junior IA, Gresta LT, Noviello Mde L, Cartelle CT, Lyon S, Arantes
RM. Leprosy classification methods: a comparative study in a referral center
in Brazil. Int J Infect Dis. 2016;45:118–22.
10. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev. 2008;79:242–53.
11. van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating
nerve damage in leprosy. A Cochrane review. Lepr Rev. 2008;79:361–71.
12. Chemotherapy of leprosy. Report of a WHO Study Group. World Health
Organ Tech Rep Ser. 1994;847:1–24.
13. Gaschignard J, Grant AV, Thuc NV, Orlova M, Cobat A, Huong NT, Ba NN, Thai
VH, Abel L, Schurr E, Alcais A. Pauci- and multibacillary leprosy: two distinct,
genetically neglected diseases. PLoS Negl Trop Dis. 2016;10:e0004345.
14. Modlin RL. Learning from leprosy: insights into contemporary immunology
from an ancient disease. Skin Pharmacol Appl Skin Physiol. 2002;15:1–6.
15. Salgame P, Yamamura M, Bloom BR, Modlin RL. Evidence for functional
subsets of CD4+ and CD8+ T cells in human disease: lymphokine patterns
in leprosy. Chem Immunol. 1992;54:44–59.
16. Cho SN, Cellona RV, Villahermosa LG, Fajardo Jr TT, Balagon MV, Abalos RM,
Tan EV, Walsh GP, Kim JD, Brennan PJ. Detection of phenolic glycolipid I of
Mycobacterium leprae in sera from leprosy patients before and after start of
multidrug therapy. Clin Diagn Lab Immunol. 2001;8:138–42.
17. Towers TL, Freedman LP. Granulocyte-macrophage colony-stimulating factor
gene transcription is directly repressed by the vitamin D3 receptor.
Implications for allosteric influences on nuclear receptor structure and
function by a DNA element. J Biol Chem. 1998;273:10338–48.
18. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin
RL. Defining protective responses to pathogens: cytokine profiles in leprosy
lesions. Science. 1991;254:277–9.
19. Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR,
Modlin RL. Cytokine patterns of immunologically mediated tissue
damage. J Immunol. 1992;149:1470–5.
20. Palermo ML, Pagliari C, Trindade MA, Yamashitafuji TM, Duarte AJ,
Cacere CR, Benard G. Increased expression of regulatory T cells and
down-regulatory molecules in lepromatous leprosy. Am J Trop Med
Hyg. 2012;86:878–83.
21. Sadhu S, Khaitan BK, Joshi B, Sengupta U, Nautiyal AK, Mitra DK. Reciprocity
between regulatory T cells and Th17 cells: relevance to polarized immunity
in leprosy. PLoS Negl Trop Dis. 2016;10:e0004338.
22. Saini C, Siddiqui A, Ramesh V, Nath I. Leprosy reactions show increased
Th17 cell activity and reduced FOXP3+ tregs with concomitant decrease in
TGF-beta and increase in IL-6. PLoS Negl Trop Dis. 2016;10:e0004592.
23. Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, Carlavan I,
Deret S, Reiniche P, Rivier M, et al. Molecular and morphological
characterization of inflammatory infiltrate in rosacea reveals activation of
Th1/Th17 pathways. J Invest Dermatol. 2015;135:2198–208.
24. Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M, Alzahrani M,
Al-Muhsen S, Halwani R, Ma CS, et al. IMMUNODEFICIENCIES. Impairment of
immunity to Candida and Mycobacterium in humans with bi-allelic RORC
mutations. Science. 2015;349:606–13.
25. Jardim MR, Illarramendi X, Nascimento OJ, Nery JA, Sales AM, Sampaio EP,
Sarno EN. Pure neural leprosy: steroids prevent neuropathy progression. Arq
Neuropsiquiatr. 2007;65:969–73.
26. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A, Liu PT, Cole
ST, Godowski PJ, Maeda Y, et al. Activation and regulation of Toll-like
receptors 2 and 1 in human leprosy. Nat Med. 2003;9:525–32.
27. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE, Graeber TG, Sieling
PA, Liu YJ, Rea TH, et al. TLR activation triggers the rapid differentiation of
monocytes into macrophages and dendritic cells. Nat Med. 2005;11:653–60.
28. Maeda Y, Mukai T, Spencer J, Makino M. Identification of an immunomodulating
agent from mycobacterium leprae. Infect Immun. 2005;73:2744–50.
29. Oliveira RB, Ochoa MT, Sieling PA, Rea TH, Rambukkana A, Sarno EN, Modlin
RL. Expression of Toll-like receptor 2 on human Schwann cells: a
mechanism of nerve damage in leprosy. Infect Immun. 2003;71:1427–33.
30. Modlin RL. The innate immune response in leprosy. Curr Opin Immunol.
2010;22:48–54.
31. Jullien D, Sieling PA, Uyemura K, Mar ND, Rea TH, Modlin RL. IL-15, an
immunomodulator of T cell responses in intracellular infection. J Immunol.
1997;158:800–6.
32. Penna GO, Pinheiro AM, Nogueira LS, Carvalho LR, Oliveira MB, Carreiro VP.
Clinical and epidemiological study of leprosy cases in the University Hospital of
Brasilia: 20 years—1985 to 2005. Rev Soc Bras Med Trop. 2008;41:575–80.
33. Bleharski JR, Li H, Meinken C, Graeber TG, Ochoa MT, Yamamura M,
Burdick A, Sarno EN, Wagner M, Rollinghoff M, et al. Use of genetic
profiling in leprosy to discriminate clinical forms of the disease.
Science. 2003;301:1527–30.
34. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage
activation. Nat Rev Immunol. 2008;8:958–69.
35. Tripp CS, Beckerman KP, Unanue ER. Immune complexes inhibit
antimicrobial responses through interleukin-10 production. Effects in
severe combined immunodeficient mice during Listeria infection. J
Clin Invest. 1995;95:1628–34.
36. Ratledge C, Dover LG. Iron metabolism in pathogenic bacteria. Annu Rev
Microbiol. 2000;54:881–941.
37. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC.
Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and
heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage
responses in vitro, in resolving skin blisters in vivo, and after
cardiopulmonary bypass surgery. Circ Res. 2004;94:119–26.
38. Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S. Role for the class A
macrophage scavenger receptor in the phagocytosis of apoptotic
thymocytes in vitro. Proc Natl Acad Sci U S A. 1996;93:12456–60.
39. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK,
Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature.
2001;409:198–201.
40. Parthasarathy S, Fong LG, Otero D, Steinberg D. Recognition of solubilized
apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the
acetyl-LDL receptor. Proc Natl Acad Sci U S A. 1987;84:537–40.
41. Terpstra V, Bird DA, Steinberg D. Evidence that the lipid moiety of oxidized
low density lipoprotein plays a role in its interaction with macrophage
receptors. Proc Natl Acad Sci U S A. 1998;95:1806–11.
42. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez
MA, Navab M, Reddy ST, Witztum JL, et al. Host-derived oxidized
phospholipids and HDL regulate innate immunity in human leprosy. J Clin
Invest. 2008;118:2917–28.
43. Job CK. Mycobacterium leprae in nerve lesions in lepromatous leprosy. An
electron microscopic study. Arch Pathol. 1970;89:195–207.
44. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and
the progression of the human tuberculosis granuloma. Nat Immunol. 2009;
10:943–8.
45. Halvorsen B, Waehre T, Scholz H, Clausen OP, von der Thusen JH, Muller F,
Heimli H, Tonstad S, Hall C, Froland SS, et al. Interleukin-10 enhances the
oxidized LDL-induced foam cell formation of macrophages by antiapoptotic
mechanisms. J Lipid Res. 2005;46:211–9.
46. de Mattos KA, Sarno EN, Pessolani MC, Bozza PT. Deciphering the
contribution of lipid droplets in leprosy: multifunctional organelles with
roles in Mycobacterium leprae pathogenesis. Mem Inst Oswaldo Cruz.
2012;107 Suppl 1:156–66.
47. Hirai KE, Aarao TL, Silva LM, de Sousa JR, de Souza J, Dias Jr LB, Carneiro FR,
Fuzii HT, Quaresma JA. Langerhans cells (CD1a and CD207), dermal
dendrocytes (FXIIIa) and plasmacytoid dendritic cells (CD123) in skin lesions
of leprosy patients. Microb Pathog. 2016;91:18–25.
48. Simoes Quaresma JA, de Oliveira MF, Ribeiro Guimaraes AC, de Brito EB, de
Brito RB, Pagliari C, de Brito AC, Xavier MB, Seixas Duarte MI. CD1a and
factor XIIIa immunohistochemistry in leprosy: a possible role of dendritic
cells in the pathogenesis of Mycobacterium leprae infection. Am J
Dermatopathol. 2009;31:527–31.
Fonseca et al. Infectious Diseases of Poverty  (2017) 6:5 Page 7 of 8
49. Massone C, Nunzi E, Ribeiro-Rodrigues R, Talhari C, Talhari S, Schettini AP,
Parente JN, Brunasso AM, Puntoni M, Clapasson A, et al. T regulatory cells
and plasmocytoid dentritic cells in hansen disease: a new insight into
pathogenesis? Am J Dermatopathol. 2010;32:251–6.
50. Massone C, Talhari C, Talhari S, Brunasso AM, Campbell TM, Curcic P, Cerroni
L, Ribeiro-Rodrigues R. Immunophenotype of skin lymphocytic infiltrate in
patients co-infected with Mycobacterium leprae and human
immunodeficiency virus: a scenario dependent on CD8+ and/or CD20+
cells. Br J Dermatol. 2011;165:321–8.
51. Motta AC, Furini RB, Simao JC, Ferreira MA, Komesu MC, Foss NT. The
recurrence of leprosy reactional episodes could be associated with oral
chronic infections and expression of serum IL-1, TNF-alpha, IL-6, IFN-gamma
and IL-10. Braz Dent J. 2010;21:158–64.
52. Scollard DM, Truman RW, Ebenezer GJ. Mechanisms of nerve injury in
leprosy. Clin Dermatol. 2015;33:46–54.
53. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy
reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis.
2006;43:e19–22.
54. Misch EA, Berrington WR, Vary Jr JC, Hawn TR. Leprosy and the human
genome. Microbiol Mol Biol Rev. 2010;74:589–620.
55. Lockwood DN, Vinayakumar S, Stanley JN, McAdam KP, Colston MJ. Clinical
features and outcome of reversal (type 1) reactions in Hyderabad, India. Int
J Lepr Other Mycobact Dis. 1993;61:8–15.
56. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK,
Schurr E, Abel L, Alcais A. Age is an important risk factor for onset
and sequelae of reversal reactions in Vietnamese patients with
leprosy. Clin Infect Dis. 2007;44:33–40.
57. Shen J, Liu M, Zhou M, Wengzhong L. Occurrence and management of
leprosy reaction in China in 2005. Lepr Rev. 2009;80:164–9.
58. Triccas JA, Winter N, Roche PW, Gilpin A, Kendrick KE, Britton WJ. Molecular
and immunological analyses of the Mycobacterium avium homolog of the
immunodominant Mycobacterium leprae 35-kilodalton protein. Infect
Immun. 1998;66:2684–90.
59. Kahawita IP, Lockwood DN. Towards understanding the pathology of
erythema nodosum leprosum. Trans R Soc Trop Med Hyg. 2008;102:329–37.
60. Stefani MM, Martelli CM, Gillis TP, Krahenbuhl JL. In situ type 1 cytokine
gene expression and mechanisms associated with early leprosy progression.
J Infect Dis. 2003;188:1024–31.
61. Tung KS, Umland E, Matzner P, Nelson K, Schauf V, Rubin L, Wagner D,
Scollard D, Vithayasai P, Vithayasai V, et al. Soluble serum interleukin 2
receptor levels in leprosy patients. Clin Exp Immunol. 1987;69:10–5.
62. Fava VM, Cobat A, Van Thuc N, Latini AC, Stefani MM, Belone AF, Ba NN,
Orlova M, Manry J, Mira MT, et al. Association of TNFSF8 regulatory variants
with excessive inflammatory responses but not leprosy per se. J Infect Dis.
2015;211:968–77.
63. Richard AC, Ferdinand JR, Meylan F, Hayes ET, Gabay O, Siegel RM. The TNF-
family cytokine TL1A: from lymphocyte costimulator to disease co-
conspirator. J Leukoc Biol. 2015;98:333–45.
64. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, Scollard
DM. Potential plasma markers of Type 1 and Type 2 leprosy reactions: a
preliminary report. BMC Infect Dis. 2009;9:75.
65. Aiba Y, Nakamura M. The role of TL1A and DR3 in autoimmune and
inflammatory diseases. Mediators Inflamm. 2013;2013:258164.
66. Smith WC, Anderson AM, Withington SG, van Brakel WH, Croft RP, Nicholls
PG, Richardus JH. Steroid prophylaxis for prevention of nerve function
impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ.
2004;328:1459.
67. Rieneck K, Diamant M, Haahr PM, Schonharting M, Bendtzen K. In vitro
immunomodulatory effects of pentoxifylline. Immunol Lett. 1993;37:131–8.
68. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis
factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp
Immunol. 1991;84:103–8.
69. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The
influence of thalidomide on the clinical and immunologic manifestation of
erythema nodosum leprosum. J Infect Dis. 1993;168:408–14.
70. Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis
factor production in patients with leprosy. Infect Immun. 1992;60:1441–6.
71. Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J,
DeBoy R, Dodson R, Gwinn M, Haft D, et al. Whole-genome comparison
of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol.
2002;184:5479–90.
72. Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, Martins RC, Sampaio
EP. Cytokine mRNA expression in leprosy: a possible role for interferon-
gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol.
1999;50:541–9.
73. Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP,
Deshpande S. Circulating cytokine profiles in leprosy patients. Lepr Rev.
2007;78:223–30.
74. Kaplan G, Britton WJ, Hancock GE, Theuvenet WJ, Smith KA, Job CK, Roche PW,
Molloy A, Burkhardt R, Barker J, et al. The systemic influence of recombinant
interleukin 2 on the manifestations of lepromatous leprosy. J Exp Med.
1991;173:993–1006.
75. Vieira AP, Trindade MA, Pagliari C, Avancini J, Sakai-Valente NY, Duarte AJ,
Benard G. Development of type 2, but not type 1, leprosy reactions is
associated with a severe reduction of circulating and in situ regulatory T-
cells. Am J Trop Med Hyg. 2016;94:721–7.
76. Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip JJ, Goulart IM, Thapa
P, Kunwar CB, van Meijgaarden KE, van den Eeden SJ, Wilson L, et al.
Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh,
Brazil, Ethiopia and Nepal. BMC Infect Dis. 2015;15:477.
77. Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melgar M,
Saul A, Estrada-Parra S, Estrada-Garcia I. IgG antibody subclasses, tumor
necrosis factor and IFN-gamma levels in patients with type II lepra reaction
on thalidomide treatment. Int Arch Allergy Immunol. 1998;116:60–6.
78. Hagge DA, Saunders BM, Ebenezer GJ, Ray NA, Marks VT, Britton WJ,
Krahenbuhl JL, Adams LB. Lymphotoxin-alpha and TNF have essential but
independent roles in the evolution of the granulomatous response in
experimental leprosy. Am J Pathol. 2009;174:1379–89.
79. Job CK. Pathology of peripheral nerve lesions in lepromatous leprosy—a light
and electron microscopic study. Int J Lepr Other Mycobact Dis. 1971;39:251–68.
80. Job CK. Nerve damage in leprosy. Int J Lepr Other Mycobact Dis. 1989;57:532–9.
81. Ng V, Zanazzi G, Timpl R, Talts JF, Salzer JL, Brennan PJ, Rambukkana A. Role
of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of
Mycobacterium leprae. Cell. 2000;103:511–24.
82. Rambukkana A, Salzer JL, Yurchenco PD, Tuomanen EI. Neural targeting of
Mycobacterium leprae mediated by the G domain of the laminin-alpha2
chain. Cell. 1997;88:811–21.
83. Rambukkana A. Molecular basis for the peripheral nerve predilection of
Mycobacterium leprae. Curr Opin Microbiol. 2001;4:21–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Fonseca et al. Infectious Diseases of Poverty  (2017) 6:5 Page 8 of 8
